









KidneyA Prospective Study on Long-Term Clinical
Outcomes of Patients With Lupus Nephritis
Treated With an Intensified B-Cell Depletion
Protocol Without Maintenance TherapyDario Roccatello1, Savino Sciascia1, Carla Naretto1, Mirella Alpa1, Roberta Fenoglio1,
Michela Ferro1, Giacomo Quattrocchio1, Elena Rubini1, Elnaz Rahbani1 and Daniela Rossi1
1CMID-Nephrology and Dialysis Unit (ERK-net Member), Center of Research of Immunopathology and Rare Diseases, Coor-
dinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences,
University of Turin and S. Giovanni Bosco Hub Hospital, Turin, ItalyBackground: We aimed to investigate the safety and efficacy of an intensified B-cell depletion induction
therapy (IBCDT) without immunosuppressive maintenance regimen compared with standard of care in
biopsy-proven lupus nephritis (LN).
Methods: Thirty patients were administered an IBCDT (4 weekly rituximab [RTX] 375 mg/m2 and 2 more
doses after 1 and 2 months; 2 infusions of 10 mg/kg cyclophosphamide [CYC], 3 methylprednisolone
pulses), followed by oral prednisone (tapered to 5 mg/d by the third month). No immunosuppressive
maintenance therapy was given. Thirty patients matched for LN class and age were selected as controls:
20 received 3 methylprednisolone pulses days followed by oral prednisone and mycophenolate mofetil
(MMF) 2 to 3 g/d, whereas 10 were given the Euro Lupus CYC. MMF (1-2 g/daily) or azathioprine (AZA, 1-2
mg/kg/day) were given for > 3 years as a maintenance therapy.
Results: At 12 months, complete renal remission was observed in 93% of patients on IBCDT, in 62.7% on MMF,
and in 75% on CYC (P ¼ 0.03); the dose of oral prednisone was lower in the IBCDT group (mean  SD 2.9  5.0
mg/dl) than MMF (10.5  8.0 mg/d, P < 0.01) or CYC group (7.5  9.0 mg/d, P < 0.01). Mean follow-up after
treatmentwas 44.5months (interquartile range [IQR] 36–120months), 48.6months (IQR 36–120months), and 45.3
(IQR 36–120 months) for IBCDT, MMF, and CYC, respectively. At their last follow-up visit, we observed no sig-
nificant differences in proteinuria and serum creatinine, nor in the frequency of new flares among the 3 groups.
Conclusion: In biopsy-proven LN, the IBCDT without further immunosuppressive maintenance therapy
was shown to be as effective as conventional regimen of MMF or CYC followed by >3-year maintenance
either MMF or AZA regimen. Moreover, the use of IBCDT was associated with a marked reduction of
glucocorticoid cumulative dose.
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International Reports (2021) 6, 1081–1087morbidity and mortality.1–6 We experienced dramatic
changes in the management of LN over the past
decades. The main cornerstones of LN treatment rely
on the optimization of CYC protocols, the introduc-
tion of novel therapeutic options such MMF, and,
more recently, calcineurin inhibitors (e.g., tacroli-
mus). Similarly, there has been a continuous effort to
design therapeutic strategies aimed at reducing the
steroid dose.7 The recently disseminated European
League Against Rheumatism recommendations sup-
port the use of MMF/mycophenolic acid and low-
dose i.v. CYC (EUROLUPUS scheme) as the treat-
ments of choice for the induction of remission. MMF
and azathioprine are the recommended options as
maintenance therapy.81081
Table 1. Baseline Characteristics
IBCDT n [ 30 MMF n [ 20 CYC n [ 10 P
Class IV,a n (%) 10 (33.3) 6 (30) 4 (40) 1
Class III/V, n (%) 10 (33.3) 6 (30) 4 (40) 1
Class V, n (%) 10 (33.3) 8 (40) 2 (20) 1
sCr mg/dl, median (IQR) 0.91 (0.6–1.5) 0.83 (0.6–1.4) 0.98 (0.6–1.7) 0.56
C3/C4 mg/dl, median (IQR) 61 (40–99)/13 (4–16) 59 (45–101)/12 (5–21) 62 (44–93)/11 (4–17) 0.63
Proteinuria g/24 h,
median (IQR)
5.0 (3.7–9.1) 4.6 (3.0–8.6) 5.2 (3.7–9.9) 0.45
Anti-dsDNA IU
median (IQR)
176 (37–212) 145 (31–189) 181 (41–199) 0.39
Albuminemia g/dl,
median (IQR)
3.0 (2.8–3.8) 2.89 (2.6–3.7) 3.0 (2.8–3.5) 0.57
Urinary red blood cells, median (IQR) 37 (10–100) 51 (5–100) 41 (5–100) 0.45
SLEDAI, median (IQR) 21.5 (14–25) 18 (14–24) 21 (16–25) 0.45
First-line treatment,a n (%) 15 (50) 10 (50) 5 (50) 1
New flare,b n (%) 9 (30) 6 (30) 3 (30) 1
Refractory LN (%) 6 (20) 4 (20) 2 (20) 1
CYC, cyclophosphamide; dsDNA, double-stranded DNA; IBCDT, intensified B-cell depletion induction therapy; IQR, interquartile range; LN, lupus nephritis; MMF, mycophenolate mofetil;
sCr, serum creatinine; SLEDAI, Systemic Lupus Erythematosus Activity Index.
aPatients with no sign of active LN in the previous 12 months.
bRapidly progressive glomerulonephritis, with >50% florid crescents feature in 2 cases treated with IBCDT and 1 case with CYC.
CLINICAL RESEARCH D Roccatello et al.: Intensified B-Cell Depletion Protocol in LNHowever, regardless of the improvement in overall
mortality and morbidity, conventional immunosup-
pression is still associated with a high incidence of side
effects, and the search for alternative therapeutic op-
tions remains a priority.7
Despite the disappointing results of randomized
controlled trials,9 targeting B cells remains an attractive
option in patients with LN.10
We previously reported the promising outcome of
patients with severe SLE treated with an IBCDT pro-
tocol, including RTX, CYC, and methylprednisolone
pulses.11,12 IBCDT proved to be safe, well-tolerated,
and effective both for the induction of remission and
for long-term remission maintenance despite the
absence of further immunosuppressive maintenance
therapies.11,12 The aim of this prospective study was to
investigate the long-term safety and efficacy of IBCDT
in patients with active LN as compared with conven-
tional immunosuppressants (CYC pulses or MMF) fol-
lowed by a 3-year maintenance MMF regimen.
METHODS
Patients
Sixty patients with active, biopsy-proven LN (48
women [80%]; 58 [97%) Caucasian, 2 (3%) Black) fol-
lowed at the CMID-Nephrology and Dialysis Unit and
Center of Research of Immunopathology and Rare
Diseases and Dialysis, S. Giovanni Bosco Hospital,
Turin, Italy (2005–2018) were enrolled in this study.
All patients fulfilled the American College of Rheuma-
tology classification criteria for SLE.13 Median age at
LN diagnosis was 42.3 years (range 23–65). SLE was
diagnosed a median of 13.5 months (0–36) before the
diagnosis of LN was made. All patients underwent a1082renal biopsy. Clinical and histological characteristics
are shown in Table 1. Renal biopsy classification was
carried out as recommended by the International So-
ciety of Nephrology 2003/Renal Pathology Society.14
Thirty-two patients (53%) were included in the
study when LN was diagnosed, 22 (37%) patients
entered the study when a LN flare occurred, and 6
(10%) patients entered due to refractory renal disease.
For this study, controls were selected among the
cohort of patients being treated for active LN at the
Center and were matched 1:1 based on LN histology,
age, and indication for treatment (newly diagnosed,
new renal flare or refractory renal disease, according to
Kidney Disease: Improving Global Outcomes
definitions).15
The clinical outcome of 12 of these patients treated
with IBCDT has previously been reported.12
Ethical Approval
All subjects provided written consent according to the
Declaration of Helsinki. This study was performed ac-




Thirty patients received IBCDT according to the
following scheme. RTX was administered intrave-
nously as previously described,11,12 at a dosage of 375
mg/m2 on days 2, 8, 15, and 22. Two more doses were
administered 1 and 2 months following the last weekly
infusion. This treatment was combined with 2 pulses of
10 mg/kg CYC (reduced, if needed, according to renal
impairment) at days 4 and 17, and 3 i.v. pulses of 15
mg/kg (days 1, 4, and 8) methylprednisolone followedKidney International Reports (2021) 6, 1081–1087
Table 2. Clinical and Serological Profile at 12 Months
IBCDT n [ 30 MMF n [ 20 CYC n [ 10 P
sCr 0.89 (0.6–1.4) 0.85 (0.6–1.4) 0.97 (0.6–1.7) 0.68
ESR, median (IQR) 10.2 (7–27) 14(8–28) 21 (8–30) 0.71
Proteinuria g/24 h, median (IQR) 0.46 (0.37–0.50) 0.71 (0.30–0.91) 0.51 (0.33–0.82) 0.78
C3/C4 mg/dl, median (IQR) 97 (79–120)/20 (11–37) 95 (81–120)/21 (13–40) 99 (80–120)/20 (10–40) 0.74
SLEDAI median, (range) 4 (1–5) 6 (2–8) 4 (2–8) 0.57
Complete renal response, n (%) 28 (93) 13 (65) 7 (70) 0.03
Partial renal response, n (%) 2 (7) 4 (20) 3 (30) 0.15
No renal response, n (%) 0 (0) 3 (15) 0 (0) 0.37
Any renal response, n (%) 30 (100) 17 (85) 10 (100) 0.32
Time to complete renal response,
median months (IQR)
9 (6–11) 8 (6–11) 7(6–11) 0.87
CYC, cyclophosphamide; ESR, erythrocyte sedimentation rate; IBCDT, intensified B-cell depletion induction therapy; IQR, interquartile range; MMF, mycophenolate mofetil; sCR, serum
creatinine; SLEDAI, Systemic Lupus Erythematosus Activity Index
D Roccatello et al.: Intensified B-Cell Depletion Protocol in LN CLINICAL RESEARCHby oral prednisone, 50 mg for 2 weeks tapered to 5 mg
in 3 months.
Controls
The patients were given 1 i.v. pulse of methylpred-
nisolone (1000 mg if body weight >50 kg, 500 mg
if <50 kg) for 3 consecutive days, followed by pred-
nisone 0.5 to 0.75 mg/kg per day for 1 month, then
tapered according to the following scheme: 0.4 to 0.5
mg/kg per day for 1 month, then 0.25 to 0.35 mg/kg
per day for 1 month, followed be a reduction of 2.5 to 5
mg every 14 days until a dosage of 5.0 to 7.5 mg daily.
Twenty patients received MMF 2 to 3 g/d, and 10 pa-
tients were administered 1 i.v. pulse of CYC every
fortnight for a total of 6 administrations (500 mg for a
total of 3000 mg).15 After 3 months of treatment, the
patients who had previously been treated with CYC
received azathioprine 1 to 2 mg/kg per day as mainte-
nance therapy in addition to prednisone. Patients who
were induced with MMF continued MMF at a dosage of
1 to 2 g/d. Maintenance therapy lasted a median of 5.5
years (range 3.7–7.0 years).
Study Outcome Measurements
Primary Outcomes
Primary outcomes were (i) complete renal remission at
12 months, and (ii) time free from flares during follow-
up.
Secondary Outcomes
Secondary outcomes included (i) changes in immuno-
logical and biochemical parameters, (ii) safety profile of
the regimens and rate of side effects, (iii) steroid-
sparing effect, (iv) response as assessed by the Sys-
temic Lupus Erythematosus Activity Index-2K, and (v)
rate of renal flares.
Definitions
European League Against Rheumatism/European Dial-
ysis and Transplant Association response to therapy
was defined as follows16:Kidney International Reports (2021) 6, 1081–1087 Complete renal response: proteinuria <0.5 g/24
hours, normal or near-normal estimated glomerular
filtration rate (within 10% of normal estimated
glomerular filtration rate if previously abnormal).
 Partial renal response: $50% reduction in proteinuria
to subnephrotic levels (<3.5 g/24 hours), and normal
or near-normal estimated glomerular filtration rate.
 No renal response: all the other cases.
Overall disease activity was assessed by Systemic
Lupus Erythematosus Activity Index-2K.17
 Severe infection: (i) deep tissue (invasive) infection
requiring i.v. or oral antibiotics used to treat infec-
tion; (ii) any infection requiring hospitalization, if
outpatient at onset; (iii) any infection leading to need
for oxygen, pressors, or fluids to support blood
pressure or intubation; (iv) pulmonary nodules that
decrease in size after a minimum 4-week course of
antifungal medications active against Aspergillus; (v)
any Bacteremia, catheter-related bloodstream infec-
tion; (vi) any infection that requires adjunctive sur-
gical intervention; (vii) disseminated or complicated
zoster (i.e., ophthalmic).
Statistical Analysis
For the comparison of variables at baseline and follow-
up, Student’s t-test was used for normally distributed
parameters and the nonparametric Mann–Whitney test
for non-normally distributed parameters. Correlations
were calculated and significance was determined by
Fisher’s exact test. Multivariable logistic regression
analysis was used to identify any independent pre-
dictors of flare. Kaplan–Meier hazard plots were con-
structed for time to renal flare. For these analyses, the
SPSS (IBM Corporation, Armonk, NY) software was
used; P < 0.05 was considered statistically significant.
RESULTS
The main characteristics of the patients at baseline are
shown in Table 1. When comparing patients treated1083
Table 3. Glucocorticoids-related Comorbidities Assessed at End of
Follow-up
IBCDT n [ 30 MMF n [ 20 CYC n [ 10 P
Osteopenia/osteoporosis, n (%)a 2 (7) 4 (20) 2 (20) 0.31
Diabetes, n (%) 1 (3) 4 (20) 1 (10) 0.16
Glaucoma, n (%) 1 (3) 4 (20) 3 (30) 0.055
IBCDT n [ 30 MMF and CYC n [ 30 P
Osteopenia/osteoporosis, n (%)a 2 (7) 6 (20) 0.12
Diabetes, n (%) 1 (3) 5 (17) 0.08
Glaucoma, n (%) 1 (3) 7 (23) 0.022
CYC, cyclophosphamide; IBCDT, intensified B-cell depletion induction therapy; MMF,
mycophenolate mofetil.
aAs assessed by bone density scan (dual-energy X-ray absorptiometry scan).
CLINICAL RESEARCH D Roccatello et al.: Intensified B-Cell Depletion Protocol in LNwith IBCDT and those who received MMF or CYC
pulses to baseline, no significant differences in terms of
serum creatinine, proteinuria, or number of red blood
cells in urinary sediment scores were observed.
At 12 months, complete renal response (CRR) had
been achieved in 28 (93%) patients treated with IBCDT,
in 13 (65%) on MMF, and in 7 (70%) on CYC; IBCDT
was found to be associated to a higher rate of response
when compared with the other regimens (P ¼ 0.03)
(Table 2). Partial renal response was observed in 2 (7%)
patients treated with IBCDT, in 4 patients on MMF
(20%), and in 3 (30%) in the CYC group. No response
was observed in 3 patients on MMF (15%). Time to CRR
did not statistically differ among the 3 groups (Table 2).
Twelve months after baseline assessment, none of
the patients in the IBCDT group had serum albumin
levels <3.5 g/dl, whereas this abnormality was
observed in 4 patients on MMF and in 2 in the CYC
group, respectively. Immunological and renal function
parameters at 12 months are shown in Table 2.
We observed a progressive reduction in the Sys-
temic Lupus Erythematosus Activity Index score in all
groups, although the decline was more marked in the
IBCDT group. A gradual improvement in the articular
and muco-cutaneous symptoms was observed in all
groups. Three patients treated with CYC showed
persistent haematological manifestations, mainly ane-
mia (low-to-moderate).
Complete peripheral blood B-cell depletion was
achieved in all patients who received IBCDT. The
CD20þ/CD19þ B cells were assessed every 3 months
for the first 18 months and every 6 months thereafter.
The CD20þ/CD19þ B cells were detectable in the cir-
culation after a median of 12.6 months (11–19 months).
Remarkably, when assessed 2 years after the beginning
of therapy with IBCDT, CD20þ B-cell count was still
lower than baseline (P > 0.05).
Ig levels were evaluated every 3 months for the first
18 months and every 6 months thereafter, with no
patients experiencing moderate to severe hypogam-
maglobulinemia (level IgG levels below 600 mg/dl).1084Patients were regularly monitored for osteopenia/oste-
oporosis with regularly scheduled bone density scan
(dual-energy X-ray absorptiometry scan) (Table 3).
Side Effects
No severe adverse events were observed in the IBCDT
group (2 cases of infusion speed-related bradycardia),
and no severe infections were reported during the
follow-up. One patient treated with IBCDT experienced
1 episode of urinary tract infection after 24 weeks from
treatment. Four patients treated with MMF experi-
enced gastrointestinal symptoms, mainly diarrhea,
requiring tapering of the MMF dosage (2 cases) or the
shift to mycophenolic acid (2 cases). One patient
developed self-limiting herpes zoster after 8 months
from the beginning of the therapy. Transient leuko-
penia was observed in 2 patients in the CYC group
(after 3 months from the beginning of the therapy). No
severe case of neutropenia was observed in the follow-
up. One patient had 1 episode of urinary tract infection
after 24 months from the first dose of CYC. One patient
in the CYC group developed transient amenorrhea.
Steroid-sparing Effects
One month after the beginning of induction therapy,
patients on IBCDT were being administered a signifi-
cantly lower dose of steroids (prednisone mean dose
25.0  5.0 mg/d) as compared with those on MMF (40.5
 15.7 mg/d, P < .01) or on CYC (35.4  41.0 mg/d,
P < 0.01). The trend was maintained after the 12th
month, with patients in the IBCDT group receiving
lower doses of steroids (prednisone mean dose 2.9  5.0
mg/dl) than those on MMF (10.5  8.0 mg/d, P < 0.01)
or CYC (7.5  9.0 mg/d, P < 0.01).
We observed an overall trend in lower rate of glu-
cocorticoids-related comorbidities in the IBCDT
(Table 3), reaching statistical significance for the
occurrence of glaucoma at the end of follow-up.
Patient Outcome Beyond Month 12
Mean follow-up after treatment was 44.5 months (IQR
36–120 months), 48.6 months (IQR 36–120 months),
and 45.3 (IQR 36–120 months) for IBCDT, MMF, and
CYC, respectively, and did not differ among the groups
(P ¼ 0.56). None of the patients entered end-stage renal
disease and none died. When comparing the outcomes
of the 3 groups at the last observation available, we
observed no statistically significant differences in terms
of serum creatinine and proteinuria levels. Conversely,
we found a higher rate of flares in patients who
received MMF (4, 20%) or CYC (2, 20%) compared
with IBCDT (3, 10%), albeit it did not reach statistical
significance (P ¼ 0.55). Mean time to flare was 57.9 
32.44 in the IBCDT, 57.3  37.52 in the MMF, andKidney International Reports (2021) 6, 1081–1087
Figure 1. Time free from flares curves in patients treated with IBCDT, MMF, or CYC. CYC, cyclophosphamide; IBCDT, intensified B-cell depletion
induction therapy; MMF, mycophenolate mofetil.
D Roccatello et al.: Intensified B-Cell Depletion Protocol in LN CLINICAL RESEARCH51.67  62.64 in the CYC groups, respectively. In the
IBCDT group, 3 patients experienced a flare after 36,
42, and 72 months, respectively. Following re-
treatment, they showed CRR over a median follow-up
of 92 months (Figure 1).DISCUSSION
B cells play a key role in the pathogenesis of SLE, as
they are involved in the production of autoantibodies
targeted against a heterogeneous pool of self-antigens,
therefore leading to inflammation and organ damage.
Intriguingly, a growing body of evidence now sup-
ports the hypothesis that B cells play a pivotal role
beyond the production of autoantibodies, including
the activation dendritic cells and the modulation of
T-cell functions (tolerance, induction of autoreactive
memory T cells, activation of Th1 and Th17 cells).
More recently, the modulatory effect on follicular B-
helper T cells has also been discussed in the patho-
genesis of SLE.17–19 Based on the previously
mentioned points, depletion of B cells might appear
to be a logical therapeutic target that could provide
clinical benefits in SLE, assuming that the in-
terventions achieve deep and sustained elimination of
pathogenic B cells.
We showed IBCDT to be a safe and effective thera-
peutic strategy in the management of patients with
severe LN.
As compared with standard treatments, IBCDT was
at least as safe and effective as standard MMF or CYC-
based regimens in inducing clinical remission. Most
importantly, despite the absence of immunosuppres-
sive maintenance regimen, IBCDT proved to have a
long-term efficacy profile similar to standard induction-
maintenance therapy. Indeed, among the patients who
achieved CRR after 12 months, 89% (25/28) remained
in remission after 1 cycle of IBCDT without any further
immunosuppressive maintenance treatment, and these
patients did not relapse. These data confirm our pre-
vious results in cases of refractory SLE10 and severe
cases of SLE.11Kidney International Reports (2021) 6, 1081–1087There are several points to be discussed when crit-
ically analyzing our results. First, to validate patients’
matching, all our patients receive a renal biopsy close
to treatment beginning. Second, one strength of our
treatment strategy is related to the relatively short time
of immunosuppression that patients treated with
IBCDT are exposed to, which remarkably reduces the
risk of possible adverse effects related to the prolonged
use of steroids and CYC.12 Long-lasting remission
without immunosuppressive maintenance therapy
makes the IBCDT regimen particularly appealing in
low-compliance patients. Pragmatically, we observed
that up to 93% of patients treated with IBCDT achieved
CRR at 12 months, with an overall 10% rate of flares
during follow-up. Ninety percent of patients experi-
enced a symptom-free period without urinary abnor-
malities for more than 120 months.
Third, it is worth mentioning that IBCDT allowed
the reduction of steroid burden without a loss in effi-
cacy, as compared with conventional regimens. In fact,
as of the third month of therapy, patients were
receiving a median dose of prednisone <5 mg, which
was significantly lower than what was being adminis-
tered in conventional protocols.
Moreover, no safety signals were observed
compared with studies with a comparable long-term
follow-up in terms of incidence of adverse events (as
reviewed in Roccatello et al.12), particularly when
referring to severe infections (not observed in our
cohort).
Based on the previously mentioned items, perhaps
we should reconsider our view on RTX, regardless of
the disappointing results of randomized controlled
trials, especially the LUNAR trial.9 Indeed, there are
several points to be considered when interpreting data
from patients of LUNAR study.
The first point is the background therapy. RTX
was given as an add-on therapy to gold standard
treatments, limiting the possibility of exploring the
differences in clinical response between non-
refractory patients and refractory patients. It is worth
mentioning that the subset of patients who were1085
CLINICAL RESEARCH D Roccatello et al.: Intensified B-Cell Depletion Protocol in LNrefractory to previous therapy represents the focus of
most of the available literature involving uncon-
trolled open studies investigating the use of RTX (as
discussed in Cervera et al.7). Indeed, Black and His-
panic individuals, who are known to be more resis-
tant to therapy than Caucasian individuals, showed a
better outcome when receiving RTX in the LUNAR
trial.9 Another point is the relatively short follow-up
of the LUNAR study, perhaps too short to demon-
strate any significant differences between the arms.
Finally, the clinical outcome parameters used in the
LUNAR study were very stringent when compared
with other studies,20 and did not include surrogate
markers of efficacy, such as the steroid dose-sparing
effect. Nevertheless, the LUNAR trial provided a
considerable body of scientific information and pro-
moted a critical debate on the characteristics of pa-
tients who might benefit from RTX treatment. The
most relevant is the extent of RTX-induced peripheral
blood B-cell depletion that is needed to achieve CRR
in LUNAR patients. This aspect has been reevaluated
recently. Incomplete peripheral blood B-cell deple-
tion might correlate with the inability to reduce
tubulointerstitial lymphoid aggregates in the kidney,
leading to an inadequate response to treatment.21
Complete clinical response at week 78 has been
associated with complete depletion of CD19 periph-
eral cells (i.e., # 0) and with a longer duration of
peripheral depletion (>71 days). Our results are
perfectly in line with these observations. Indeed, all
our IBCDT-treated patients who had CRR at 12
months achieved a complete peripheral depletion
(i.e., CD19 # 0).
Limitations of the Study
The open, nonblinded design of our study and the
relatively limited number of enrolled subjects might
represent limitations when interpreting our results.
These aspects are counterbalanced by the fact that our
data are supported by a long-term follow-up in a cohort
of real-life, biopsy-proven LN patients. Moreover, this
is the first study in which the efficacy and safety
profile of a combined IBCDT regimen was compared
with standard CYC- or MMF-based protocols.
CONCLUSIONS
Although a large-scale randomized controlled trial is
warranted to confirm our findings, in this prospective
study we showed that the IBCDT regimen is at least as
effective as MMF or CYC pulses in inducing remission
in patients with active LN. Furthermore, patients
treated with IBCDT achieved at least comparable results
in terms of efficacy and long-lasting remission as
standard regimens. This was maintained with minimal1086doses of prednisone starting from the end of the third
month after IBCDT without further immunosuppres-
sive maintenance therapy. This approach prevented
prolonged immunosuppression and remarkably
reduced the risk of steroid-related adverse effects.DISCLOSURE
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